Fig. 3From: MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in CanadaAbsolute utilisation rates over pre-MAG-CP (2005–11) and MAG-CP (2011–2015) eras. a Optimal use. b Appropriate use. The solid black line indicates the median overall rate and each coloured line represents one of the 11 participating centresBack to article page